MYO - Myomo, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
2.22
+0.03 (+1.37%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.19
Open2.29
Bid1.89 x 1000
Ask0.00 x 4000
Day's Range2.11 - 2.29
52 Week Range1.74 - 11.40
Volume93,775
Avg. Volume186,490
Market Cap27.56M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-0.85
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.50
Trade prices are not sourced from all markets
  • ACCESSWIRE3 days ago

    Myomo to Present at The MicroCap Conference

    / ACCESSWIRE / September 18, 2018 / Myomo, Inc. (NYSE American: MYO) ("Myomo" or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it will be presenting at The MicroCap Conference on Monday, October 1st at 11:00 AM EDT, Track 1, Essex House in New York City. Chairman and Chief Executive Officer Paul R. Gudonis and Chief Financial Officer Ralph A. Goldwasser will be presenting, as well as meeting with investors. A webcast of the presentation will be available at the Investor Relations page of the Company's website.

  • IPO Edge3 months ago

    One Year into Reg A+ IPOs, Investment Banker Predicts New Class of Securities to Drive Growth

    Mark Elenowitz Says Security Token Offerings May Thrive via Reg A+ We recently sat down for lunch in Manhattan with Mark Elenowitz, CEO of TriPoint Global Equities, to discuss the anniversary of the IPO of Myomo, a wearable medical products company that he took public in the first Reg A+ deal to list on a […]

  • Business Wire9 days ago

    Myomo Announces Continued Momentum Across Europe

    Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company, today announced continued momentum across Europe with the appointment of John Frijters as Business Development Manager for EU, a distributor agreement with Bandagist Jan Nielsen to deliver MyoPro to patients across Denmark and the first screening day in the United Kingdom.

  • IPO-Edge.com3 months ago

    One Year into Reg A+ IPOs, Investment Banker Predicts New Class of Securities to Drive Growth

    Mark Elenowitz Says Security Token Offerings May Thrive via Reg A+ We recently sat down for lunch in Manhattan with Mark Elenowitz, CEO of TriPoint Global Equities, to discuss the anniversary of the IPO of Myomo, a wearable medical products company that he took public in the first Reg A+ deal to list on a […]

  • GlobeNewswirelast month

    Analysis: Positioning to Benefit within Quanex Building Products, Molecular Templates, Atara Biotherapeutics, Forward Industries, Apollo Endosurgery, and Myomo — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK,, Aug. 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates
    Zackslast month

    Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates

    Myomo, Inc. (MYO) delivered earnings and revenue surprises of -10.53% and 1.94%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wirelast month

    Myomo Announces Second Quarter 2018 Financial Results

    Achieved Revenue Growth of 106%

  • ACCESSWIRElast month

    Myomo, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Myomo, Inc. (NYSE American: MYO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern Time. ...

  • Business Wire2 months ago

    Myomo to Report Second Quarter 2018 Results on August 7, 2018

    Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company, today announced that it will release its financial results for the second quarter 2018 on Tuesday, August 7, 2018, after the US markets close. The Company will host a conference call on Tuesday, August 7, 2018 at 4:30 p.m. EDT featuring remarks by Paul R. Gudonis, Chairman and Chief Executive Officer, and Ralph A. Goldwasser, Chief Financial Officer. The conference call, webcast and accompanying slides can be accessed through Myomo’s Investor Relations page.

  • ACCESSWIRE2 months ago

    Today’s Free Research Reports Coverage on Neovasc and Three More Healthcare Stocks

    Under assessment this morning are these four equities: Myomo Inc. (NYSE AMER: MYO), Neovasc Inc. (NASDAQ: NVCN), Smith & Nephew PLC (NYSE: SNN), and Insulet Corp. (NASDAQ: PODD). All you have to do is sign up today for this free limited time offer by clicking the link below.

  • Business Wire2 months ago

    Myomo Appoints Micah Mitchell as Chief Commercial Officer

    Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company, announced today that Micah Mitchell is joining the company as chief commercial officer (CCO), a newly created executive role. The addition of a CCO reflects Myomo’s transition from a controlled introduction of its proprietary MyoPro product line to expansion of its sales, marketing, and distribution activities to address the large unmet need of expanded mobility for individuals with arm and hand paralysis.

  • Business Wire3 months ago

    Research Team Presents Promising Preliminary Results from TBI Study Using Myomo’s MyoPro

    Researchers from the Northwestern University Prosthetics-Orthotics Center (NUPOC) and the Cleveland VA Medical Center have presented promising preliminary case reports from a clinical trial that evaluates the effects of the MyoPro myoelectric arm orthosis (powered brace) from Myomo on traumatic brain injury (TBI) patients at the Cleveland VA Medical Center. The study, which began in 2016 and is funded by the U.S. Department of Defense, includes veterans and non-veterans with TBI who have limited arm or hand functionality. Participants in the study received nine weeks of therapy and training with the MyoPro, followed by nine weeks of home use, with intermittent functional evaluations.

  • ACCESSWIRE3 months ago

    Free Pre-Market Technical Recap on MiMedx Group and Three Additional Medical Equipment Stocks

    LONDON, UK / ACCESSWIRE / June 18, 2018/ If you want a free Stock Review on MDXG sign up now at www.wallstequities.com/registration. WallStEquities.com has selected the following stocks for review this morning: Masimo Corp. (NASDAQ: MASI), Medtronic PLC (NYSE: MDT), MiMedx Group Inc. (NASDAQ: MDXG), and Myomo Inc. (NYSE AMER: MYO).

  • Top High Growth Stocks This Week
    Simply Wall St.3 months ago

    Top High Growth Stocks This Week

    Investors tend to look for stocks that have a strong future outlook. Why invest in something that will grow slower than the rest of the market? In terms of profitabilityRead More...

  • Myomo Brings MyoPro to Adolescent Patients
    Business Wire4 months ago

    Myomo Brings MyoPro to Adolescent Patients

    Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company, today announced that its MyoPro myoelectric arm orthosis (powered brace) is now available to adolescent patients with paralyzed or weakened arms. MyoPro is the only lightweight wearable device on the market that can help restore substantial functionality in the arms and hands of individuals who are suffering from the effects of a neuromuscular disease or injury. Myomo originally developed MyoPro to assist adults suffering from brachial plexus injury (BPI), brain or spinal cord injury, stroke, multiple sclerosis or ALS.

  • Business Wire4 months ago

    Myomo Announces MyoPro Availability in 16 New U.S. Locations

    Myomo®, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced agreements with leading orthotics and prosthetics practices to bring MyoPro® availability to 16 new U.S. locations. Today’s announcement includes an agreement with Limb Lab, an independently owned and operated boutique prosthetic and orthotic company, to cooperate in two new markets: Jacksonville, Florida, and Scottsdale (Phoenix area), Arizona. Several medical and rehabilitation centers with national acclaim have locations in Jacksonville and Scottsdale.

  • Business Wire4 months ago

    Myomo® Application for Medicare Codes Receives Favorable Preliminary Decision

    Myomo, Inc. (NYSE American:MYO) (“Myomo,” or the “Company”), a wearable medical robotics company, announces that the Centers for Medicare & Medicaid Services ("CMS") has published a favorable preliminary decision regarding the Company’s application for Healthcare Common Procedure Coding System (HCPCS) “L” codes. "We are very grateful to CMS and the whole HCPCS Workgroup for their preliminary decision to assign L Codes for our MyoPro line of powered orthoses," said Myomo Chief Medical Officer Dr. Brandon Green. "The MyoPro has already helped so many patients with neurological/neuromuscular injury and illness by supporting their weakened arms, restoring control over their range of motion, reducing their healthcare costs, and giving them back their independence.

  • Business Wire4 months ago

    Myomo, Inc. Issues May 2018 Shareholder Letter

    Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today issued a letter to shareholders to give an update on first quarter 2018 and ongoing MyoPro® commercial activities. Welcome to the third edition of our Investor Relations digital shareholder letter as we continue to keep you informed about Myomo's progress.

  • Business Wire4 months ago

    Myomo Reports First Quarter 2018 Results

    Myomo, Inc. , a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today reports its financial results for the first quarter ended March 31, 2018.

  • Business Wire5 months ago

    Myomo to Report First Quarter 2018 Results on May 9, 2018

    Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that it will release its financial results for the first quarter 2018 on Wednesday, May 9, 2018, after the US markets close. The Company will host a conference call on Wednesday, May 9, 2018 at 4:30 p.m. EDT featuring remarks by Paul R. Gudonis, Chairman and Chief Executive Officer, and Ralph A. Goldwasser, Chief Financial Officer.

  • Business Wire5 months ago

    Myomo Announces Free Screening Days in Over 20 Cities Nationwide

    Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, announces a nationwide program of free screening days to be held in collaboration with its Centers of Excellence, other orthotics and prosthetics practices and its rehabilitation therapy partners. Myomo and its partners will offer potential users a convenient chance to be evaluated by clinical specialists and to examine a MyoPro powered brace for themselves to determine if MyoPro might help them overcome upper-limb paralysis caused by stroke, brachial plexus injury or other neuromuscular disease or injury.

  • ACCESSWIRE6 months ago

    SeeThruEquity Issues Update on Myomo, Inc.

    NEW YORK, NY / ACCESSWIRE / March 22, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued ...

  • Business Wire6 months ago

    UPDATE - Myomo Reports Fourth Quarter and Year End 2017 Results

    Myomo, Inc. , a commercial stage medical robotics company, today announced that it is updating its previous release that was made on March 7, 2018 to incorporate certain disclosures that are required under the NYSE AMERICAN Company Guide Sections 401 and 610 .